As of today (2024-05-06), the Trailing Annual Dividend Yield of TCR2 Therapeutics is 0.00%.
The historical rank and industry rank for TCR2 Therapeutics's Dividend Yield % or its related term are showing as below:
TCRR's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.46 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
TCR2 Therapeutics Dividend Yield % Historical Data
The historical data trend for TCR2 Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TCR2 Therapeutics's Dividend Yield %
For the Biotechnology subindustry, TCR2 Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCR2 Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCR2 Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where TCR2 Therapeutics's Dividend Yield % falls into.
TCR2 Therapeutics Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of TCR2 Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
TCR2 Therapeutics (TCR2 Therapeutics) Business Description
TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TCRR has been successfully added to your 